Littlepage Booth
Contact Littlepage Booth
Risperdal (risperidone) is an antipsychotic drug that changes a person’s brain chemistry and causes the production of a hormone called prolactin. Although FDA only approved Risperdal to treat symptoms of schizophrenia in adults, Janssen encouraged pediatrician and pediatric doctors to widely prescribe this mediation to children for a broad range of mood and behavior issues. Promotion of a drug for such a population without FDA approval is illegal.  Even worse, Janssen’s clinical trials and internal documents showed a real risk of young boys developing female breasts due to taking Risperdal. Yet Janssen misrepresented this risk and instead assured doctors that Risperdal was safe.  Thousands of young boys who took this drug developed female breasts (gynecomastia) leading to significant disfigurement, rampant bullying at school and serious emotional stress. The only way to remove the female breasts is by double mastectomy surgeries. Even though Janssen (a division of Johnson & Johnson) knew of this side effect, it failed to properly study this issue or provide adequate warnings to doctors.

Littlepage Booth Leckman is actively prosecuting Risperdal cases on behalf of boys who grew female breasts because of their use of this drug. Trials for LBL clients will continue throughout the Fall of 2022 and Spring of 2023 in Philadelphia, PA.

Prior Philadelphia jurors have shown outrage at Janssen’s misconduct and reckless misrepresentations about the risks of Risperdal and have brought back significant verdicts in favor of the injured boys, including:

Date Plaintiff Jury Verdict
October 2019 Murray

$8 Billion – Punitive Damages   $1.75 Million – Compensatory Damages
July 2016 Yount

$70 Million – Compensatory Damages   Punitive damage issue awaiting trial
February 2015 Pledger

$2.2 Million – Compensatory   Punitive damage issue awaiting trial

If you or someone you love took this medication and developed breast growth, please call (713) 529-8000 to speak to one of our attorneys.